ClinicalTrials.gg

Program

onvuzosiran sodium

Also written as “ADX-324”, “ADX-324 Dose Level 1” and “ADX-324 Dose Level 2”.

Its studies are mostly in Angioedemas, Hereditary, led by ADARx Pharmaceuticals.

Furthest: phase 3, since Apr 7, 20253 company-led studies, 3 open or runningNext primary completion: Nov 30, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
ADARx Pharmaceuticals33 open or runningphase 3since Apr 7, 2025Dec 16, 2022Nov 30, 2027phase 3 · NCT06960213

Also a collaborator on its studies: Avance Clinical Pty.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 16, 2022First study: phase 2 study in Angioedemas, HereditaryFirst studyNCT05691361 · 53 enrolled · Australia
  2. Apr 7, 2025Phase 3 study in Angioedemas, HereditaryNCT06960213 · 90 planned · United States, Argentina, Australia and more
  3. Feb 19, 2026Phase 3 study in Angioedemas, HereditaryNCT07428499 · 90 planned · United States, Argentina, Australia and more

Ahead

  1. Nov 30, 2027Primary completion: phase 3 study in Angioedemas, HereditaryNCT06960213
  2. Dec 31, 2027Primary completion: phase 2 study in Angioedemas, HereditaryNCT05691361
  3. Jun 30, 2030Primary completion: phase 3 study in Angioedemas, HereditaryNCT07428499

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07428499Angioedemas, Hereditary · United States, Argentina, Australia and more3RecruitingJun 30, 203090
NCT06960213Angioedemas, Hereditary · United States, Argentina, Australia and more3RecruitingNov 30, 202790
NCT05691361Angioedemas, Hereditary · Australia2Active, not recruitingDec 31, 202753

How it is read

Names in the registry

  • “ADX-324”, 2 entries
  • “ADX-324 Dose Level 1”, 1 entry
  • “ADX-324 Dose Level 2”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.